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1. Introduction
b-Hydroxy ketones are important building blocks for the syn-
thesis of chiral 1,3-amino alcohols, 1,3 diamines, 1,3-hydroxy acids
used for the preparation of naturally occurring molecules and
those of pharmaceutical interest as well.1–3 Indeed, they provide
the scaffold for the synthesis of different classes of drugs such as
fluoxetine, duloxetine, atomoxetine, atorvastatin, ezetimibe and
selective inhibitors of the serotonin and norepinephrine reuptake.4
These drugs, in the absence of a valid alternative, are bound to
retain a vast sales volume on pharmaceutical market with about
11.9 $ billions sold in 2011 and with a projected sale of about
13.4 $ billions for 2018.5
Different synthetic approaches have been optimized to produce
b-hydroxynitriles relying on the asymmetric transfer hydrogena-
tion of b-ketonitriles with the employment of chiral organic and
inorganic catalysts yielding the corresponding aminoalcohols after
a simple Pd/C reduction of the nitrile moiety.6–9
Unfortunately, high production costs along with an environ-
mentally hazardous metal toxicity have hampered the use of this
type of catalyst especially for the synthesis of products useful to
the pharmaceutical industry.
A valid alternative emerging for the production of these useful
intermediates is the use of biocatalysts, i.e. the kinetic resolution
starting from racemic mixtures of b-hydroxynitriles catalyzed by
lipases and nitrilases10–12 or the enantioselective reduction of
b-ketonitriles catalyzed by ketoreductases.13–15 Over the last
http://dx.doi.org/10.1016/j.tetasy.2016.04.002
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e employed as biocatalysts in the reduction of b-ketonitriles. The red
ubra, was selected as the best performing catalyst in the reduction of dif-
giving total stereoselectivity in most cases (90–99% ee). In particular, its
ells was expanded to a semi-preparative scale for the production of the
le at ScienceDirect
Asymmetry
sevier .com/locate / tetasyrawas screened in the reduction of alkylation products in comparison with
of configuration of products 2a and 11a after derivatisation with S-MPA.
 2016 Published by Elsevier Ltd.
decade different isolated carbonyl reductases have been employed
in the reduction of these valuable precursors although their
application was correlated to the presence of redox cofactors thus
inevitably introducing the need for fine tuning the appropriate
60cofactor recycle system.16–19 In contrast, the use of whole cells
could overcome this unprofitable drawback.
In this regard the use of bakers’ yeasts in the reduction of
b-ketonitriles allows products with high enantiomeric excesses in
an (S)-configuration to be obtained, but in low yields due to the
competitive non-stereoselective reductive a-alkylation secondary
reaction leading to the insertion of an ethyl group at the
b-position; the formation of this by-product is due to the presence
of acetaldehyde deriving from microorganism metabolism.20–23
The reaction equilibrium could be shifted in favour of the reduction
70products over the alkylation ones by using a biphasic system or by
a precise monitoring of the reaction temperature, albeit with a
decrease of reaction rates and yields.23
Dehli et al. had previously studied the reduction of
b-ketonitriles employing fungus Curvularia lunata whole cells
achieving the S configuration of the product in 77% yield and also
in this case the formation of the alkylation reaction products.24
Moreover, this biocatalyst was able to reduce in a diastereo- and
enantioselective manner the corresponding alkylation products,
in exactly the opposite way from Saccharomyces cerevisiae, and
80thus allowing chiral substituted b-hydroxynitriles to be obtained
simply by modulating growth and biotransformation reaction
conditions. Conversely, alkylation products were totally lacking
when recombinant Escherichia coliwhole cells were employed. This
type of cell, in fact, were proved to over express ketoreductases
allowing the isolation of both enantiomers of the product.16
etry (2016), http://dx.doi.org/10.1016/j.tetasy.2016.04.002
Indeed, in the literature the most relevant attempts relative to
the obtainment of these valuable scaffolds in an enantiopure form
appeared to be focused on the stereoselective reduction of benzoy-
lacetonitrile precursors. For these reasons the selection of new bio-
90 catalysts able to selectively reduce b-keto nitriles bearing different
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cially those ones that avoid the use of cofactor recycle systems for
accomplishing the desired products in higher yields.
2. Results and discussion
The use of whole cells in the reduction reactions is attractive as
it gives the possibility of exploiting the microbial metabolism for
the redox cofactor recirculation. On the other hand, the production
of acetaldehyde as a by-product generally results in low yields of
the desired product due to the competitive reductive alkylation
reaction occurring, especially with substrates that are very acti-
vated as in the case of b-ketonitriles (Scheme 1).
Herein selected aerobic and facultative anaerobic yeasts were
evaluated for their ability to reduce a series of substituted
b-ketonitriles. The preliminary screening was realized only with
the aim to address the reaction in favour of the reduction product
1a, using as standard substrate the 3-oxo-3-(thiophen-2-yl)propa-
nenitrile 1, whose reduction product is the valuable precursor of
duloxetine. All the reactions were conducted in presence of glucose
Table 1
Biotransformation of 3-oxo-3-(thiophen-2-yl)propanenitrile 1 using glucose as co-substra
Entry Microorganisms 1a
(%)a ee (%)b
1 Saccharomyces marzianus CBS397 —
2 Pichia pini CBS 744 —
3 Pichia pastoris CBS 2612 —
4 Saccharomyces cerevisiae Zeus —
5 Sporobolomyces holsaticus NCYC 420 —
6 Sporobolomyces tsugae CBS 503 —
7 Kluyveromyces marxianus CBS1553 —
8 Lindnera fabianii CBS 5640 18 58 (S)
9 Pichia glucozyma CBS 5766 —
10 Pichia henricii CBS 5765 12 61 (R)
11 Pichia etchelsii 19 58 (R)
12 Torulopsis magnoliae IMAP 4425 87 67 (R)
13 Torulopsis molischiana CBS 837 34 29 (S)
14 Sporidiobolus pararoseus SD2 53 62 (S)
15 Sporobolomyces salmonicolor MIM 100 73 (S)
16 Rhodotorula rubra MIM146 100 97 (S)
17 Rhodotorula rubra MIM147 100 98 (S)
a Molar conversion and de% were calculated by 1H NMR analysis.
b Ee% was determined by HPLC analysis using OJ-H Chiralcel as chiral column (hexan
c Ee% was determined by HPLC analysis in accordance to literature conditions.14
Please cite this article in press as: Rimoldi, I.; et al. Tetrahedron: Asymm(50 g/L) as co-substrate. The results obtained after 48 h of biotrans-
formation are reported in Table 1.
Similarly to what has been reported in the literature,20 many of
the yeasts screened in this work were able to transform substrate 1
in the reductive alkylation product 2 (entries 1–13), although dif-
ferent behaviours were highlighted. In the case of S. cerevisiae
and of other anaerobic yeasts the substrate 1 is totally converted
into the product 2 as evidenced by entries 1–7. In the other cases
the formation of reduction products 1a and 2a was observed as
in biotransformation by Curvularia lunata CECT 2130, studied by
Dehli and Gotor,13 obtaining an enantiomerically enriched product
nevertheless with poor diastereomeric excesses of product 2a
(entries 8–13). Despite the low molar conversion, P. henricii was
the only yeast able to give a good enantiomeric excess in favour
of diastereomers in with (R,R)- and (S,R)-configurations of
substrate 2 (entry 10). Only the red yeasts, known to be aerobic
2aNAD(P)+NAD(P)H
ketonitriles with whole-cells.ones, allowed the reduction product 1a to be obtained with an
(S)-configuration (entries 14–17) with moderate-to-high enan-
tiomeric excess (62–98%) and without the formation of by-prod-
ucts. Alcohol 1a was instead obtained with the (R)-configuration
using as biocatalyst Tourolopsis magnoliae, still in good yield and
130ee (entry 12). On substituting the glucose as co-substrate with
ethanol, which is easily oxidised into acetaldehyde, a general
increase in the reductive alkylation product 2 was observed. This
concurrent reaction was particularly evident when red yeasts were
te
2 2a
(%)a (%)a de (%)a ee anti (%)c ee syn (%)c
100 —
100 —
100 —
100 —
97 —
100 —
91 —
79 —
89 12
80 8 39 syn 97 RR 95 SR
70 11 1 anti 14 SS 37 SR
0 13 2 syn 38 RR 46 SR
0 66 18 anti 65 SS 46 RS
0 —
0 —
0 —
0 —
e:2-propanol = 90:10, flow = 1.0 mL/min, k = 230 nm).
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good enantiomeric excess in favour of SS diastereomer (Table 2).
Taking into consideration the high enantioselectivity shown by
R. rubra MIM 147 in the reduction of 3-oxo-3-(thiophen-2-yl)
propanenitrile 1 (Table 1, entry 3), the scope of its particularly
interesting biocatalytic performance was expanded to the reduc-
tion of different substituted aryl b-ketonitriles. In particular, the
use of resuspended cells that were grown for 48 h was compared
to the use of lyophilised cells at a concentration of 20 g L1 (dry
weight) successively resuspended in 0.1 M phosphate buffer at
pH = 7 or resuspended in tap water (Table 3).
The reduction of the carbonyl group, independent of the
reaction media, proceeded with a high reaction rate in 24 h by
employing resuspended cells and afforded the reduction product
only in the (S)-configuration in all cases. The only exception was
observed in the case of a deactivated substrate as 6 (49%, entry
5). When the biocatalyst was employed in a lyophilised form a
general decrease in the reaction rate was seen, probably as a con-
sequence of a possible partial inactivation by the dehydrogenases.
As an exception, a total molar conversion after 72 h of the substrate
can be observed in the case of the unsubstituted aryl 4 (entry 3) or
with the heterocyclic aromatic substrates 1 and 3 (entries 2 and 3)
where the heteroatom is in the a-position to the carbonyl group.
When the aromatic ring is differently substituted, the best results
in terms of conversion were seen in the presence of a para activat-
Table 2
Biotransformations of 3-oxo-3-(thiophen-2-yl)propanenitrile 1 using ethanol as co-substr
Entry Microorganisms 1a
(%)a ee (%)b
1 Sporobolomyces salmonicolor MIM 38 61 S
2 Rhodotorula rubra MIM146 17 97 S
3 Rhodotorula rubra MIM147 12 98 S
4 Sporidiobolus pararoseus SD2 21 82 S
a Molar conversion and de% were calculated by 1H NMR analysis.
b Ee% was determined by HPLC analysis using OJ-H Chiralcel as chiral column (hexan
c Ee% was determined by HPLC analysis in accordance to literature conditions.14
Table 3
Reductive biotransformation of different aryl substituted b-ketonitriles using R. rubra as b
R
O
1 R=
S
O
R'
3 R=
R=
Rhodotorula rub
1-10
N
Entry Substrate Resuspended cells
Molar conversion (%)a
1 1 100
2 3 100
3 4 100
4 5 100
5 6 49
6 7 100
7 8 97
8 9 95
9 10 100
a Molar conversion (%) after 24 h was calculated by 1H NMR analysis.
b Molar conversion (%) after 72 h. Ee% was determined by HPLC analysis using OJ-H C
Please cite this article in press as: Rimoldi, I.; et al. Tetrahedron: Asymming substituent (entries 6 and 8) whereas the presence of a deacti-
vating group in themeta (substrates 6 and 10, entries 5 and 9) or in
the para position (substrates 5 and 8, entries 4 and 7), lowered the
molar conversion Anyway, the ee% of the desired alcohols is very
high (94–99%) in all cases, confirming that R. rubra is a useful cat-
alyst in the reduction of activated ketonitriles. With the aim of
evaluating the possibility to produce semi-preparative amounts
of (S)-3-hydroxy-3-(thiophen-2-yl)propanenitrile, a precursor of
duloxetine, biotransformations were carried out using different
substrate concentrations: 2, 4, 6 or 10 g L1 in tap water. Substrate
inhibition was not observed either at lower or higher concentra-
170tions up to 10 g L1, even if, as expected, a decrease in molar con-
version was highlighted starting from 6 g L1 (complete conversion
in 48 h). In fact after 12 h the biotransformation was complete for
2 g L1 concentration and in 24 h for 4 g L1 concentration. After
chromatographic purification starting from 1 g of 1, 786 mg of 1a
were obtained. When 10 g L1 substrate concentration was added,
80% yield was achieved in 96 h and the reaction didn’t proceed fur-
ther. In all cases stereoselectivity in favour of the (S)-enantiomer
remained constant (98–99%).
As the results obtained in this preliminary study highlighted
180that using ethanol as co-substrate and R. rubraMIM 147 as the bio-
catalyst the reductive alkylation product 2 is preferentially
obtained (Table 2, entry 3), product 2a is not formed. Substrates
2, 11 and 12 were synthesised choosing Saccharomyces cerevisiae,
ate
2 2a
(%)a (%)a de (%)a ee anti (%)c ee syn (%)c
42 20 71 anti 77 SS 8 RS
78 5 50 anti 68 SS 12 RS
88 0
74 5 41 anti 73 SS 52 RS
e:2-propanol = 90:10, flow = 1.0 mL/min, k = 230 nm).
iocatalyst
4 R'=H
5 R'= p-CH3
6 R'=m-CH3
7 R'= p-OCH3
8 R'= p-F
9 R'= p-CF3
10 R'=m-Cl
(S)-1a-10a
R
OH
ra MIM147 N
Lyophilised cells
ee (% of S) Molar conversion (%)b ee (% of S)
97 100 >99
97 100 98
97 100 98
97 31 96
94 51 90
99 100 99
96 15 99
96 90 98
96 3 94
hiralcel as chiral column (hexane:2-propanol = 90:10, flow 1 mL/min, k = 216 nm).
etry (2016), http://dx.doi.org/10.1016/j.tetasy.2016.04.002
190
the enantiomeric excess for the anti-diastereomers was very high
(95–98%) although the diastereomeric excess was influenced by
the different aryl group in a position to the carbonyl.
2.1. Assignment of configuration for 2a and 11a
200
210
R
O
R
OH
Rhodotorula rubra MIM147
2 R= 11 R= 12 R=
2-11-12 2a-11a-12a
R
O
1-3-4
S. cerevisiae
S O
N
N N
Scheme 2. Biotransformation by S. cerevisiae affording substrates 2, 11 and 12.
Table 4
Reductions of different rac-2-arylbutanenitrile using R. rubra MIM147 as biocatalyst
Entry Substrate de anti (%) ee anti (% of S,S) ee syn (% of R,S)
1 2 66 97 50
2 11 76 95 0
3 12 90 98 28
c
re (a), S-MPA derivatives (b) and HPLC chromatogram (c) for 11a.
Q7
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of substrates under suitable reaction conditions (Scheme 2).
These substrates are particularly interesting to study due to the
presence of additional stereogenic centre14 so the second part of
this research work focused on the capability to reduce and resolve
the diastereomers of the corresponding reduction products. The
results are summarized in the following table (Table 4).
As reported in our previous work25 for substrate 12, after 48 h
the biotransformations were realized using a substrate
concentration of 1 g L1 for all employed substrates. In all cases
Ee% was determined by HPLC analysis using Phenomenex Cellulose 4 as chiral
column (hexane:2-propanol = 90:10, flow 1 mL/min, k = 230 nm).
Figure 1. Comparison among 1H NMR spectra of racemic mixtuPlease cite this article in press as: Rimoldi, I.; et al. Tetrahedron: AsymmThe configuration for diastereomeric mixture of 12a was
reported in literature.9,14 The assignment of the configuration for
diastereomers of 2a and 11a was realised using R. rubra MIM147
as biocatalyst, able to preferentially form the anti-(S,S)-diastere-
omer (Table 4) and Pichia henricii CBS 5765, forming the
anti-(R,R)-diastereomer and one syn-(S,R)-diastereomer with high
ee% (Table 1, entry 10). Employing directly compounds 2 and 11
as substrate for biotransformations the reduction reaction
conducted with P. henricii compared to R. rubra proceeded slowly
but when substrate concentrations was equal to 1 g L1 and
concentration resuspended was 40 g L1 (dry weight), an increase
of diastereomeric excess for 2a was observed (63% de syn). In the
case of substrate 11 a diastereomeric excess of 85% syn was
achieved. The reactions were completed after 72 h.etry (2016), http://dx.doi.org/10.1016/j.tetasy.2016.04.002
220 230
Q8
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tial comparison of: 1H NMR spectra with the corresponding ones
obtained after derivatisation with (S)-MPA (a-methoxy-phenyl
acetic acid),26 HPLC profiles of racemic mixture respectively of 2a
and 11a (Figs. 1 and 3) and those ones achieved by reduction with
R. rubra and P. henricii (Figs. 2 and 4).
As reported in Figure 1 a racemic mixture of 11a obtained by
reduction with NaBH4 was analyzed by 1H NMR spectroscopy
before (Fig. 1a) and after reaction with S-MPA in presence of
4-DMAP and DCC (Fig. 1b). In Figure 1c the corresponding HPLCR.
e (aFigure 2. HPLC chromatograms for racemic mixture of 11a, reduction products from
MPA-derivatives (b).
Figure 3. Comparison among 1H NMR spectra of racemic mixturPlease cite this article in press as: Rimoldi, I.; et al. Tetrahedron: Asymmanalysis was reported using chiral column Phenomenex Lux Cellu-
lose 4 (hexane:2-propanol = 90:10, flow 1 mL/min, k = 230 nm).
From 1H NMR spectra, the biotransformation with R. rubra, an
enantiomeric excess of 95% in favour of diastereomers with an
anti-configuration was obtained based on the literature configura-
tion assignment.14 On the contrary on reduction with P. henricii the
syn diastereomers were predominant (63% de). By comparison of
HPLC chromatograms and 1H NMR spectra of MPA-derivatives it
was possible to assign the configurations to all the four diastere-
omers (Fig. 2a and b).
rubra and from P. henricii (a) compared with the corresponding 1H NMR spectra of
), derivatives with MPA (b)) and HPLC chromatogram (c) for 2a.etry (2016), http://dx.doi.org/10.1016/j.tetasy.2016.04.002
240
250
260
270
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R. ru
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the four diastereomers obtained by reduction of 2a as reported
in the following Figures 3 and 4.
3. Conclusion
In conclusion the strategy to use the aerobic yeasts allows the
amount of alkylation product during biotransformation of ketoni-
triles to be reduced. Thus, in the presence of ethanol, that was
Figure 4. HPLC chromatograms for racemic mixture of 2a, reduction products from
derivatives (b).directly converted into acetaldehyde, a major production of alky-
lated product was seen. Rhodotorulara rubrawas revealed as a valid
biocatalyst for the reduction of different substituted ketonitriles
using either fresh whole cells or lyophilised ones. The semiprepar-
ative production of dulexetine’s (S)-precursor in very good
enantiomeric was realized using tap water as reaction solvent in
4 g/L substrate concentration. The assignment of configuration of
the four diastereomeric reduction products of 2a and 11a was
easily realised thanks to the possibility to obtain the enriched
products by Rhodotorula rubra versus Pichia henricii.
4. Experimental
4.1. General methods
1H and 13C NMR spectra were recorded in CDCl3 on Bruker
Avance 300 MHz equipped with a non-reverse probe. Chemical
shifts (in ppm) were referenced to residual solvent proton/carbon
peak. Polarimetry analyses were carried out on Perkin Elmer 343
Plus equipped with Na/Hal lamp. MS analyses were performed by
using a Thermo Finnigan (MA, USA) LCQ Advantage system MS
spectrometer with an electronspray ionisation source and an ‘Ion
Trap’ mass analyser. The MS spectra were obtained by direct infu-
sion of a sample solution in MeOH under ionisation, ESI positive.
Catalytic reactions were monitored by HPLC analysis with Merck-
Hitachi L-7100 equipped with Detector UV6000LP and chiral col-
umn (OJ-H Chiralcel, OD-H Chiralcel or Phenomenex Lux Cellulose
4). FTIR spectra were collected by using a Perkin Elmer (MA, USA)
FTIR Spectrometer ‘Spectrum One’ in a spectral region between
4000 and 450 cm1 and analysed by transmittance technique with
32 scansions and 4 cm1 resolution. Commercially reagent grade
solvents were dried according to standard procedures and freshly
distilled under nitrogen before use.
4.2. Microorganisms: culture conditions
Strains from official collections or from our collection were
routinely maintained on a malt extract (8 g L1 agar 15 g L1,
Please cite this article in press as: Rimoldi, I.; et al. Tetrahedron: AsymmpH = 5.5). In order to obtain cells for the biocatalytic activity tests,
the microorganisms were grown on solid medium for 72 h at 28 C
and then they were cultured in 1000 mL Erlenmeyer flasks con-
taining 100 mL of the medium (OD530nm mL1 = 0.1 at t0).The
microorganisms were incubated for 48 h at 28 C on a reciprocal
shaker (100 rpm). The yeasts were grown on malt extract with
5 g L1 Difco yeast extract pH = 5.6, excepting for Sporidiobolus
pararoseus SD2 that grown on YPD medium (10 g L1 Difco yeast
extract, 10 g L1 peptone, 20 g L1 glucose). Fresh cells from sub-
bra and from P. henricii (a) compared with corresponding 1H NMR spectra of MPA-merged cultures were centrifuged (4000g for 15 min at 4 C)
and washed with tap water before using. In the case of Rhodotorula
rubra MIM147 the cells were also lyophilised. The cells used in the
screening biotransformations were concentrated in ratio 1:2.
4.3. General procedure of biotransformation
The biotransformation screening was carried out in 10 ml-
screw capped test tubes re-suspending the yeast cells in 5 mL of
0.1 M phosphate buffer pH = 7 containing 50 g L1 of glucose (or
ethanol 10 g L1) and adding 2 g L1of substrate 1 dissolved in
290DMSO (1%). The reaction mixtures were magnetically stirred at
28 C for 48 h. The product was extracted with diethyl ether
(2  5 mL), dried with Na2SO4 and the solvent was removed in
vacuo. The samples were analysed by 1H NMR to determinate the
molar conversion and the diastereomeric excess while the
enantiomeric excess was recorded by HPLC equipped with OD-H
Chiralcel, eluent: hexane:2-propanol = 95:5, flow = 0.8 mL/min,
k = 230 nm; rt: 1a: (S) = 49.9 min, (R) = 52.2 min; 2 = 23.9 min;
2a: (S,S) = 26.5 min, (R,S) = 28.8 min, (S,R) = 34.3 min, (R,R) =
36.4 min.14
3001a: 1H NMR (CDCl3, 300 MHz, 25 C): d = 1.13 (t, J = 7.3 Hz, 3H),
2.88 (d, J = 5.9 Hz, 2H), 5.27–5.34 (m, 1H), 7.00 (t, J = 4.8 Hz, 1H),
7.10 (d, J = 3.3 Hz, 1H), 7.32 (d, J = 4.7 Hz, 1H) ppm; 13C NMR
(CDCl3, 75 MHz, 25 C): d = 28.43, 66.38, 117.33, 124.93, 125.95,
127.33, 144.75 ppm. IR m = 3429, 2922, 2254, 1413, 1040, 850,
709 cm1. MS (ESI) of C7H7NOS (m/z): calcd 153.2, found 175.8
[M+Na+].
2: 1H NMR (CDCl3, 300 MHz, 25 C): d = 1.14 (t, J = 7.3 Hz, 3H),
1.99–2.15 (m, 2H), 4.11–4.18 (d, J = 6.2, J = 1.4 Hz, 1H), 7.15–7.20
(m, 1H), 7.75 (d, J = 7.6 Hz, 1H) 7.84 (d, J = 6.7 Hz, 1H) ppm; 13C
310NMR (CDCl3, 75 MHz, 25 C): d = 11.82, 24.36, 42.62, 117.37,
128.92, 133.86, 136.82, 141.16, 183.62 ppm. IR m = 3094, 2974,
2934, 2248, 1671, 1413, 1247, 1206, 1064, 731 cm1. MS (ESI) of
C9H9NOS (m/z): calcd 179.2, found 201.8 [M+Na+].
2a: 1H NMR (CDCl3, 300 MHz, 25 C): d = 1.09 (t, J = 7.4 Hz, 3H,
anti), 1.12 (t, J = 7.4 Hz, 3H, syn), 1.51–1.68 (m, 2H, anti), 1.69–1.8
(m, 2H, syn), 1.58 (br, -OH), 2.82–2.92 (m, 2H, anti), 2.94–2.99
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(m, 2H, syn), 5.05 (d, J = 6.3 Hz, 1H, anti), 5.08 (d, J = 6.5 Hz, 1H,
syn), 6.99–7.10 (m, 1H, syn + anti), 7.11 (d, J = 3.6 Hz, 1H, anti),
7.13 (d, J = 3.1 Hz, 1H, syn), 7.32 (d, J = 5.2 Hz, 1H, anti + syn)
320 ppm; 13C NMR (CDCl3, 75 MHz, 25 C): d = 11.77 (syn), 11.83 (anti),
21.69 (syn), 22.69 (anti), 42.81 (syn), 43.23 (anti), 69.87 (syn), 70.16
(anti), 120.01 (syn), 120.14 (anti), 125.55 (anti), 125.7 (syn), 125.97
(syn), 126.02 (anti), 127.2 (anti + syn), 143.71 (syn), 144.05
(anti) ppm. IR m = 3435, 2970, 2933, 2245, 1711, 1461, 1032,
706 cm1. MS (ESI) of C9H11NOS (m/z): calcd 181.27, found 204.8
[M+Na+].
4.4. Screening of different aryl ketonitriles with Rhodotorula
rubra MIM147
Fresh cells and lyophilised cells of Rhodotorula rubra MIM147
330 were used 20 g L1 dry weight re-suspended in phosphate buffer
or in tap water with 50 g L1 of glucose; then the substrates 1,
3–10 were dissolved in DMSO and added at 2 g L1 concentration.
For substrate 1, biotransformations were also carried out at 4, 6 or
10 g L1 concentration.
HPLC conditions:6,8 OJ-H Chiralcel, eluent: hexane:2-propa-
nol = 90:10, flow = 1.0 mL/min, k = 216 nm.
Compound 1a: (S) = 32.1 min, (R) = 38.3 min; compound 3a rt
(S) = 22.2 min, (R) = 25.8 min; compound 4a rt (S) = 23.4 min,
(R) = 29.7 min; compound 5a rt (S) = 20.6 min, (R) = 24.4 min;
340 compound 6a rt (S) = 18.5 min, (R) = 22.0; compound 10a rt
(S) = 23.7 min, (R) = 28.6 min; compound 7 rt (S) = 47.7 min,
(R) = 49.5 min; compound 8a rt (S) = 21 min, (R) = 27.7 min;
compound 9 rt (S) = 15.5 min, (R) = 17.9 min.
4.5. Enzymatic reduction of rac-2-(thiophene-2-carbonyl)
butanenitrile 2, rac-2-(furan-2-carbonyl)butanenitrile 11 and
rac-2-benzoylbutanenitrile 12
Commercial Baker’s yeast (50 g L1) was suspended in a phos-
phate buffer (200 mL, 0.1 M, pH = 7) containing 50 g L1 of glucose
and 5 g L1 of the substrate (1, 3 or 4) was added. The biotransfor-
350 mation system was shaken with mechanic stirrer at 28 C. When
the total conversion was achieved, the cells were separated by cen-
trifugation. Both the aqueous phases and the cells mixture were
extracted with diethyl ether (3x50 mL), dried with Na2SO4 and
the solvent was removed in vacuo.
2: The crude product was purified by flash chromatography
(cyclohexane/diisopropyl ether = 7:3) to give 1.04 g of 2 (88%
yield).
11: The crude product was purified by flash chromatography
(CH2Cl2/cyclohexane/ethyl acetate = 4:1:1) to give 929 mg of 11
360 (77% yield). 1H NMR (CDCl3, 300 MHz, 25 C): d = 1.14
(t, J = 7.4 Hz, 3H), 2.02–2.09 (m, 2H), 4.11–4.16 (q, J = 6.2, 4.3 Hz,
1H), 6.61–6.64 (dd, J = 3.6 Hz, J = 1.9 Hz, 1H), 7.40 (d, J = 4.4 Hz,
1H) 7.68 (s, 1H) ppm; 13C NMR (CDCl3, 75 MHz, 25 C): d = 11.73,
23.66, 41.91, 113.45, 117.06, 119.93, 147.88, 150.57, 179.74 ppm.
IR m = 3135, 2964, 2933, 2249, 1681, 1567, 1464, 1394, 1261,
1021, 771 cm1. MS (ESI) of C9H9NO2 (m/z): calcd 163.2, found
185.8 [M+Na+].
12: The crude product was purified by flash chromatography
(CH2Cl2/hexane/ethyl acetate = 4:1:1) to give 1.02 g of 12 (86%
370 yield). 1H NMR (CDCl3, 300 MHz, 25 C): d = 1.16 (t, J = 7.7 Hz,
3H), 2.02–2.15 (m, 2H), 4.30 (dd, J = 6.2, 4.3 Hz, 1H), 7.49–7.56
(m, 2H), 7.65 (d, J = 7.6 Hz, 1H) 7.95 (d, J = 6.7 Hz, 2H) ppm;
13C NMR (CDCl3, 75 MHz, 25 C): d = 11.71, 23.77, 41.69,
117.41, 128.92–134.63, 170.91, 190.97 ppm. IR m = 3467, 2975,
2936, 2249, 1694, 1597, 1449, 1265, 1233, 1208, 1000,
696 cm1. MS (ESI) of C11H11NO (m/z): calcd 173.2, found
196.1 [M+Na+].
4.6. Synthesis of rac-2-(hydroxy(thiophen-2-yl)methyl)buta-
nenitrile 2a, rac-2(furan-2-yl(hydroxyl)methyl)butanenitrile
38011a and rac-2-(hydroxyl(phenyl)methyl)butanenitrile 12a
The rac-2a, rac-11a and rac-12a were obtained by reduction of
the substrates 2, 11 and 12 (1 equiv) in ethanol with NaBH4
(1.5 equiv). The reactions were magnetically stirred at room tem-
perature for 4 h and extracted with water and ethyl acetate
(3  50 mL), dried with Na2SO4 and the solvent was removed in
vacuo.
2a: HPLC conditions: column: Phenomenex Lux Cellulose 4,
eluent: hexane:2-propanol = 90:10, flow = 1 mL/min, k = 230 nm;
rt: (R,S) = 6.43 min, (S,S) = 8.73 min, (S,R) = 7.94 min, (R,R) =
39010.27 min.
11a: 1H NMR (CDCl3, 300 MHz, 25 C): d = 1.10 (t, J = 7.4 Hz, 3H,
anti), 1.11 (t, J = 7.4 Hz, 3H, syn), 1.54–1.76 (m, 2H, anti + syn),
2.97–3.08 (m, 2H, anti + syn), 4.80 (d, J = 6.3 Hz, 1H, anti), 4.85 (d,
J = 6.8 Hz, 1H, syn), 6.36–6.39 (m, 2H, anti), 6.41 (d, J = 3.3 Hz, 1H,
syn), 6.45 (d, J = 3.3 Hz, 1H, syn), 7.41–7.43 (m, 1H, anti + syn)
ppm;13C NMR (CDCl3, 75 MHz, 25 C): d = 11.71 (syn), 11.82 (anti),
21.67 (syn), 22.65 (anti), 40.09 (syn), 40.49 (anti), 67.64 (syn), 67.92
(anti), 108.35 (anti) 108.50 (syn), 110.79 (syn + anti), 119.81 (syn),
119.99 (anti), 143.06 (syn + anti), 152.78 (syn + anti) ppm. IR
m = 3434, 2971, 2936, 2244, 1730, 1462, 1149, 745 cm1. MS (ESI)
of C9H11NO2 (m/z): calcd 165.3, found 187.9 [M+Na+]. HPLC condi-
tions: column: Phenomenex Lux Cellulose 4, eluent: hexane:2-pro-
panol = 90:10, flow = 1 mL/min, k = 216 nm; rt: (R,S) = 6.43 min,
(S,S) = 9.95 min, (S,R) = 7.38 min, (R,R) = 11.49 min.
12a: 1H NMR (CDCl3, 300 MHz, 25 C): d = 1.09 (t, J = 7.7 Hz, 3H,
anti), 1.17 (t, J = 7.6 Hz, 3H, syn), 1.51–1.69 (m, 2H), 2.76–2.83 (m,
2H, anti), 2.87–2.95 (m, 2H, syn), 4.79 (d, J = 6.2 Hz, 1H, anti), 4.83
(d, J = 6.6 Hz, 1H, syn), 7.33–7.56 (m, 5H) ppm; 13C NMR (CDCl3,
75 MHz, 25 C): d = 9.84 (syn), 10.38 (anti), 24.86 (anti), 25.87
410(syn), 41.43 (anti), 42.51 (syn), 76.86 (syn), 77.46 (anti), 127.04
(syn + anti), 128.05 (anti), 128.22 (syn), 128.55 (anti), 128.69
(syn), 140.61 (anti), 141.42 (syn) ppm. FTIR m = 3390, 2964, 1494,
1453, 160, 1103, 1038, 702 cm1. MS (ESI) of C11H11NO (m/z): calcd
175.1, found 198.3 [M+Na+]. HPLC conditions: column: OD-H Chi-
ralcel, eluent: hexane: 2-propanol = 95:5, flow = 0.8 mL/min,
k = 216 nm. rt: (R,S) = 25.6 min, (S,S) = 26.5 min, (S,R) = 34.6 min,
(R,R) = 36.0 min.
4.7. 2-(Hydroxy(thiophen-2-yl)methyl)butanenitrile 2a and 2
(furan-2-yl(hydroxyl)methyl)butanenitrile 11a derivatisation
420The enantiomerically enriched mixtures of 2a and 11a were
obtained by biotransformation using fresh cells of Rhodotorula
rubra MIM 147 (20 g L1 dry weight) and Pichia henricii CBS 5765
(40 g L1 dry weight) suspended in phosphate buffer 0.1 M
pH = 7 containing 50 g L1 of glucose. Compounds 2 or 11were dis-
solved in DMSO and added to the biotransformation system to a
final substrate concentration of 1 g L1 in presence of 1% solvent.
After 72 h the reactions were extracted with diethyl ether
(3  50 mL), dried with Na2SO4 and the concentrated at reduce
pressure. The crude products 2a and 11a were purified by column
430chromatography on silica gel (CH2Cl2/cyclohexane/ethyl
acetate = 4:1:1).
1H NMR of the corresponding derivatives with MPA (a-meth-
oxy-phenyl acetic acid): To a solution of rac-2a and rac-11a and
the enriched products obtained by biotransformation (1 equiv) in
CDCl3 (0.75 mL), S-(+)-MPA (1 equiv), 4-DMAP (0.5 equiv) and
DCC (1.5 equiv) were added.26
1H NMR for 2a (CDCl3, 300 MHz, 25 C) d = 6.08 (d, J = 7.1 Hz,
1H, (S,R)-syn), 6.10 (d, J = 7.1 Hz, 1H, (R,S)-syn), 6.14 (d, J = 6.8 Hz,
1H, (R,R)-anti), 6.15 (d, J = 6.8 Hz, 1H, (S,S)-anti) ppm. 1H NMR for
44011a (CDCl3, 300 MHz, 25 C) d = 6.10 (d, J = 3.3 Hz, 1H, (S,S)-anti),
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6.17 (d, J = 3.3 Hz, 1H, (R,S)-syn), 6.20–6.23 (m, 1H, (S,S)-anti), 6.24–
6.26 (m, 1H, (R,S)-syn), 6.20–6.23 (m, 1H, (R,R)-anti), 6.34–6.36 (m,
1H, (S,R)-syn), 6.44 (d, J = 3.3 Hz, 1H, (R,R)-anti) ppm.
4.8. Synthesis of (S)-3-hydroxy-3-(thiophen-2-yl)propanenitrile
1a with Rhodotorula rubra MIM 147
Cells obtained by centrifugation (4000g for 15 min at 4 C) of
the culture broth (500 mL) were washed with tap water
(3  200 mL) and re-suspended in 250 mL of tap water containing
50 g L1 of glucose. 1 g of 1 was dissolved in DMSO and added to
450 the biotransformation system to give 4 g L1 of substrate concen-
tration and 1% of solvent. The biotransformation system was sha-
ken with mechanic stirrer at 28 C for 24 h. The cells were
separated by centrifugation and the two fractions were extracted
with diethyl ether (3  100 mL), the combined organic layer was
dried with Na2SO4 and the solvent was removed in vacuo. The
crude product was purified by flash chromatography (ethyl
acetate/cyclohexane = 7:3) to give 786 mg of (S)-2a (78% yield).
(S)-1a: All characterization data are in agreement with previously
reported. [a]D20 = 42.1 (c 0.8, CHCl3).
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